As one of the most influential academic events in the global oncology community, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3 (Central Daylight Time) in Chicago, USA. This prestigious gathering brings together leading experts, researchers, and clinicians from around the world to spotlight the latest advances, breakthrough therapies, and emerging paradigms in cancer prevention and treatment.

Amid the evolving challenges of cancer treatment, GoBroad’s clinical team continues to pursue patient-centric innovation, advancing care where unmet needs persist. At ASCO 2025, GoBroad team will present three original research studies, demonstrating the team’s ongoing clinical exploration and practice in immunotherapy, allogeneic transplantation strategies, and cell-based therapies.

 Poster Presentations

Abstract 4040

Title:
Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.

Authors:

• First Author: Meili Sun
• Corresponding Author: Jin Li

Abstract 5533

Title:
GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.

Authors:

• First & Corresponding Author: Haifeng Qin

Abstract 6536

Title:
Potential benefits of using a different donor for transplantation consolidation after donor-derived CD7 CAR T.

Authors:

• First & Corresponding Author: Jing Pan

Guided by a mission to put patients first and powered by research, the Gaobo team remains committed to advancing the frontiers of cellular and immunotherapy. By pushing the boundaries of precision medicine, we strive to bring long-term survival and better outcomes to more cancer patients worldwide.

Stay tuned as we continue to share real-time updates and highlights from ASCO 2025—we look forward to engaging with the global oncology community and driving forward the next wave of breakthroughs.